Iran's drug supply strains under heightened US sanctions

Iran is facing a growing scarcity of essential medicines, with Al Jazeera reporting that a significant portion of the population can no longer obtain or afford life‑saving drugs. Government officials, however, maintain that the country's pharmaceutical sector remains functional and will not collapse despite the pressure.

The shortage follows a recent escalation in U.S. sanctions that target Iran's ability to import medical equipment and pharmaceutical ingredients. The new restrictions, imposed in early 2026, expand on earlier measures that barred the export of high‑technology components and limited the use of the SWIFT banking system for Iranian firms. By tightening the financial and logistical pathways that Iranian drug manufacturers rely on, the United States aims to increase pressure on Tehran over its nuclear program, but the policy has also tightened the flow of critical health supplies.

Hospitals and pharmacies across major cities such as Tehran, Isfahan and Mashhad report dwindling stocks of insulin, chemotherapy agents and broad‑spectrum antibiotics. Prices for the few available products have risen sharply, pushing many patients into a situation where treatment is either delayed or unaffordable. The scarcity is not limited to imported brand‑name drugs; even locally produced generic medicines are feeling the squeeze as raw material imports become harder to secure.

Iran's pharmaceutical industry has long depended on imported active pharmaceutical ingredients (APIs) and specialized equipment. Since the re‑imposition of sanctions after the 2018 nuclear deal collapse, the sector has struggled to achieve self‑sufficiency, despite state‑led initiatives to develop domestic production capacity. The current wave of sanctions revives a familiar challenge: balancing political pressure with the need to safeguard public health. Historically, similar sanctions episodes have led to black‑market activity and reduced vaccination coverage, underscoring the broader societal risks.

In response, Tehran's health ministry has announced plans to accelerate local manufacturing, seek alternative supply routes through friendly nations, and allocate emergency funds to subsidize critical drugs. Analysts warn that without a diplomatic breakthrough or a relaxation of the sanctions, the health system could face prolonged strain, potentially increasing morbidity and mortality rates among vulnerable groups. The situation highlights the complex interplay between international policy and everyday access to healthcare in sanctioned nations.